NEUARTIGE ALPHA4BETA7-DIMERANTAGONISTEN

European patent · EP2906584 · Deleted

Register entry

Publication number
EP2906584
Application number
EP13845982
Kind
European patent with effect for Switzerland and Liechtenstein
Status
Deleted
Specification
Granted
Filed
Oct 11, 2013
Published
Aug 19, 2015
Granted
Nov 20, 2019
Deleted
Oct 31, 2020
Reason
Annual fee unpaid
IPC classes
A61K 38/00 (2006.01)
C07K 14/47 (2006.01)
C07K 14/705 (2006.01)
Priority
US 201261712722 P 11.10.2012
US 201361807714 P 02.04.2013
US 201314050349 10.10.2013
PCT application
PCT/US2013/064439 11.10.2013
PCT publication
WO2014/059213 17.04.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 19, 2021

    Deleted, fee unpaid

    Published in Swissreg on 19.05.2021

  2. Nov 20, 2019

    Granted

    Published in Swissreg on 20.11.2019

Parties

Holder

Protagonist Therapeutics, Inc.

Protagonist Therapeutics Inc.

521 Cottonwood Drive Suite A, Milpitas, California 95035, US

Inventor

MATTHEAKIS, Larry C.

Cupertino California 95014, US

BHANDARI, Ashok

Pleasanton California 94588, US

PATEL, Dinesh V.

Fremont California 94539, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.